Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everybody and welcome to Recursion's third quarter 2025 learnings call. My name is Chris Gibson. I'm the co-founder and current CEO of Recursion and I'm so delighted to have you all joining us today. I want to start off by talking about something that I'm really excited about, which is our executive leadership updates. And it's my pleasure to share with all of you that beginning January 1st, the amazing Nijat Khan is going to take over the role of CEO, President, and Director of Recursion. I've been working with Nijat for the past 18 months in an incredible partnership to build our platform, to deliver on our pipeline and our partnerships. And everything that I have seen has convinced me that she is absolutely the right leader to take Recursion through its next chapter. And I'm so delighted that she has agreed to take on that role. I'm also incredibly excited that I'm going to continue bringing my passionate, unapologetic founder energy to Recursion as the chairman of the board and as an executive advisor. And finally, I want to say a huge thank you to our entire board and especially to our chairman, Rob Hirschberg, He's been an amazing chair and an incredible mentor to myself and Najat. And I am delighted that he's going to continue on with us, I hope for a very long time, as our vice chairman and lead independent director. These are really exciting changes that I believe are going to position Recursion to affect our mission to lead the tech biospace. And I am so, so thrilled to get to share them with you today. Najat? Thank you, Chris. It is such an honor to step into the big role to be CEO and president of Accursion. And I want to thank you. I want to thank the board and just our incredible team for the trust and partnership. And Chris, first for a few minut...